Slingshot members are tracking this event:
Phase 1/2 preliminary results of NKTR-214 (PEG-rhuIL-2) in combination with nivolumab in advanced solud tumors (PIVOT trial)
- Source Link:
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jun 02, 2018
- Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs MRK, ARMO, NKTR Executed On: Apr 30, 2018 at 10:00 AM EDT
Related Keywords Il-2, Nktr-214, Interleukin, Cytokine, Cancer Immunotherapy, Opdivo, Checkpoint Inhibitor, Pd-1 Checkpoint Inhibitor